CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry
Por:
de la Torre, EP, Serrano, J, Barragán, E, Ayala, R, Calasanz, MJ, Chillón, MC, Soria, E, Bilbao-Sieyro, C, Cabello, A, Lavilla-Rubira, E, Gallego, AA, Gómez, JL, Simón, JAP, Rodríguez-Veiga, R, Martínez-Cuadrón, D, Vives, S, Burgues, JMB, Alis, FI, Gil, C, Algarra, LA, Castaño, T, Tormo, M, del Castillo, TB, Sánchez, MDM, Casado, M, Fernández, OA, Herrera-Puente, P, Vicente, MBV, Colorado, M, Toscano, MDM, González, BJ, Ruiz, MP, Rubio, MO, Sánchez-García, J and Montesinos, P
Publicada:
8 ene 2026
Resumen:
The aim of our study was to analyze the incidence, co-mutation pattern, and prognostic impact of CEBPA gene mutations in a large multicenter consecutive series of 1367 adult patients AML patients treated with non-IT modalities. A total of 83 patients (6.1%) had mutations in CEBPA gene. Among these, 34 (2.5%) harbored mutations located in bZIP domain (bZIP in-frame N = 6) and 49 (3.6%) in other regions of the gene (other CEBPAmut). Genes most frequently co-mutated in these CEBPAmut patients were TET2 (45.8%, N = 38), SRSF2 (42.2%, N = 35), and ASXL1 (40.9%, N = 34). Using the Bradley-Terry model we identified that mutations in MDS-related genes, in TP53, and in epigenetic regulators appear to occur earlier. In contrast, genes involved in activating cell signaling appeared to occur later than CEBPAmut. Overall Survival (OS) of non-IT AML patients was analyzed according to the type of CEBPAmut. Median OS was 11.6 months in CEBPA-bZIP patients compared to 9.0 and 6.9 for patients with other CEBPAmut or CEBPAwt, respectively. When selecting 1129 AML patients treated with HMA or HMA-based combinations, CEBPA-bZIP patients had a median survival time of 11.6 months (range 9.6-NR) and 2.5 years survival probability of 20.1% which were outcomes comparable to remaining ELN2024 favorable patients. We concluded that our series of non-IT AML patients within the PETHEMA registry confirm a low percentage of CEBPA mutated cases which are frequently co-mutated with MDS related genes. Those CEBPA-bZIP cases harbor a similar median OS than those belonging to favorable ELN2024 risk category.
Filiaciones:
de la Torre, EP:
Univ Cordoba UCO, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIBIC, Hematol Unit, Cordoba, Spain
Serrano, J:
Univ Cordoba UCO, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIBIC, Hematol Unit, Cordoba, Spain
Barragán, E:
Hlth Res Inst La Fe IIS La Fe, Biomed Res Networking Ctr Oncol CIBERONC, Valencia, Spain
La Fe Univ, Clin Anal Serv, Accredited Hematol Res Grp, Valencia, Spain
Polytech Hosp, Hlth Res Inst La Fe IIS La Fe, Valencia, Spain
Ayala, R:
Univ Complutense Madrid, 12 Octubre Univ Hosp, Spanish Natl Canc Res Ctr CNIO, Dept Med, Madrid, Spain
Calasanz, MJ:
Univ Navarra, Navarra Inst Hlth Res IdiSNA, Hematol Dis Lab, CIMA LAB Diagnost, Pamplona, Spain
Chillón, MC:
Salamanca Univ Hosp HUS IBSAL, Canc Res Ctr IBMCC USAL CSIC, Hematol Dept, CIBERONC, Salamanca, Spain
Soria, E:
Univ Seville, Virgen del Rocio Univ Hosp, Inst Biomed Seville IBIS, CSIC, Seville, Spain
Cabello, A:
Nuestra Senora de Candelaria Univ Hosp, Santa Cruz De Tenerife, Spain
Gallego, AA:
Leon Univ Hosp, Leon, Spain
Gómez, JL:
Burgos Univ Hosp, Burgos, Spain
Simón, JAP:
Univ Seville, Virgen del Rocio Univ Hosp, Inst Biomed Seville IBIS, CSIC, Seville, Spain
Rodríguez-Veiga, R:
Polytech Hosp, Hlth Res Inst La Fe IIS La Fe, Valencia, Spain
La Fe Univ, Hematol Dept, Accredited Hematol Res Grp, Valencia, Spain
Martínez-Cuadrón, D:
Polytech Hosp, Hlth Res Inst La Fe IIS La Fe, Valencia, Spain
La Fe Univ, Hematol Dept, Accredited Hematol Res Grp, Valencia, Spain
:
Hosp Germans Trias i Pujol, Josep Carreras Leukaemia Res Inst, ICO, Badalona, Spain
Burgues, JMB:
San Pedro de Alcantara Hosp, Caceres, Spain
Alis, FI:
Valencia Gen Hosp, Valencia, Spain
Gil, C:
Alicante Gen Hosp, Alicante, Spain
Algarra, LA:
Albacete Gen Hosp, Albacete, Spain
Castaño, T:
Fdn Jimenez Diaz Univ Hosp, Madrid, Spain
Tormo, M:
Univ Valencia, Univ Clin Hosp, INCLIVA Hlth Res Inst, Valencia, Spain
Sánchez, MDM:
Univ Complutense Madrid, 12 Octubre Univ Hosp, Spanish Natl Canc Res Ctr CNIO, Dept Med, Madrid, Spain
Casado, M:
Infanta Cristina Univ Hosp Badajoz, Badajoz, Spain
Fernández, OA:
Basurto Univ Hosp, Bilbao, Spain
Vicente, MBV:
Salamanca Univ Hosp, Salamanca, Spain
Colorado, M:
Marques de Valdecilla Univ Hosp, Santander, Spain
Toscano, MDM:
Virgen Macarena Univ Hosp, Seville, Spain
González, BJ:
Univ Hosp Canary Isl, Santa Cruz De Tenerife, Spain
Ruiz, MP:
Doctor Peset Univ Hosp, Valencia, Spain
Rubio, MO:
Lozano Blesa Univ Clin Hosp, Zaragoza, Spain
Sánchez-García, J:
Univ Cordoba UCO, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIBIC, Hematol Unit, Cordoba, Spain
Montesinos, P:
Hlth Res Inst La Fe IIS La Fe, Biomed Res Networking Ctr Oncol CIBERONC, Valencia, Spain
Polytech Hosp, Hlth Res Inst La Fe IIS La Fe, Valencia, Spain
La Fe Univ, Hematol Dept, Accredited Hematol Res Grp, Valencia, Spain
Univ Las Palmas Gran Canaria, Dr Negrin Univ Hosp Gran Canaria, Las Palmas Gran Canaria, Spain
Lucus Augusti Univ Hosp, Lugo, Spain
Cent Univ Hosp Asturias, Univ Inst Oncol IUOPA, Inst Hlth Res Principal Asturias ISPA, Oviedo, Spain
Puerta de Hierro Majadahonda Univ Hosp, Madrid, Spain
|